CN106511819A - 一种用于动物退热的中药组合物 - Google Patents
一种用于动物退热的中药组合物 Download PDFInfo
- Publication number
- CN106511819A CN106511819A CN201611218182.5A CN201611218182A CN106511819A CN 106511819 A CN106511819 A CN 106511819A CN 201611218182 A CN201611218182 A CN 201611218182A CN 106511819 A CN106511819 A CN 106511819A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- chinese
- fever
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 206010037660 Pyrexia Diseases 0.000 title claims abstract description 30
- 241001465754 Metazoa Species 0.000 title claims abstract description 29
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 claims abstract description 40
- 239000010231 banlangen Substances 0.000 claims abstract description 27
- 241001598107 Imperata Species 0.000 claims abstract description 25
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 25
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 25
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims description 128
- 235000013399 edible fruits Nutrition 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 26
- 240000004307 Citrus medica Species 0.000 claims description 24
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 23
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 23
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 23
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 23
- 240000001579 Cirsium arvense Species 0.000 claims description 20
- 235000005918 Cirsium arvense Nutrition 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 17
- 240000006688 Telosma cordata Species 0.000 claims description 15
- 235000017352 Telosma cordata Nutrition 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 30
- 239000000463 material Substances 0.000 abstract description 25
- 208000031295 Animal disease Diseases 0.000 abstract description 2
- 244000025254 Cannabis sativa Species 0.000 abstract description 2
- 230000007123 defense Effects 0.000 abstract 1
- 239000010135 fructus aurantii immaturus Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 63
- 229940079593 drug Drugs 0.000 description 48
- 238000012360 testing method Methods 0.000 description 29
- 239000000341 volatile oil Substances 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 20
- 241000282898 Sus scrofa Species 0.000 description 19
- 201000010099 disease Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 239000000284 extract Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 230000036760 body temperature Effects 0.000 description 17
- 241000287828 Gallus gallus Species 0.000 description 16
- 235000013330 chicken meat Nutrition 0.000 description 16
- 239000012467 final product Substances 0.000 description 15
- 239000003182 parenteral nutrition solution Substances 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 238000002156 mixing Methods 0.000 description 11
- 238000010171 animal model Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000012856 packing Methods 0.000 description 10
- 241000282887 Suidae Species 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 208000032625 disorder of ear Diseases 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000010255 intramuscular injection Methods 0.000 description 6
- 239000007927 intramuscular injection Substances 0.000 description 6
- 244000144972 livestock Species 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 229920000053 polysorbate 80 Polymers 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- 208000010359 Newcastle Disease Diseases 0.000 description 5
- 230000001754 anti-pyretic effect Effects 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 244000144977 poultry Species 0.000 description 5
- 235000013594 poultry meat Nutrition 0.000 description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000002221 antipyretic Substances 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 4
- 229960004306 sulfadiazine Drugs 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000606860 Pasteurella Species 0.000 description 3
- 208000012287 Prolapse Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000011122 softwood Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000001293 FEMA 3089 Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020741 Hyperpyrexia Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 208000001705 Mouth breathing Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000026475 palpebral edema Diseases 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 210000000697 sensory organ Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- 235000015099 wheat brans Nutrition 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000027312 Bursal disease Diseases 0.000 description 1
- MRABAEUHTLLEML-UHFFFAOYSA-N Butyl lactate Chemical compound CCCCOC(=O)C(C)O MRABAEUHTLLEML-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000202347 Porcine circovirus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000027954 Poultry disease Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000001068 allium cepa oil Substances 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001191 butyl (2R)-2-hydroxypropanoate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000005321 cobalt glass Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical class [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-N disulfurous acid Chemical compound OS(=O)S(O)(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000469 flunixin meglumine Drugs 0.000 description 1
- MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- -1 parabens Chemical compound 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于动物疾病治疗与防御领域,具体涉及一种用于动物退热的中药组合物,由以下重量份原料组分制备而成,柴胡190‑210份、防风170‑190份、板蓝根140‑160份、紫花地丁90‑110份、小蓟90‑110份、莲子心90‑110份、白茅根90‑110份、枳实40‑60份,本发明公开的中药组合物可以和安乃近一起使用,安乃近价格低廉,中药为常见药材,施用方便,又能达到更好的效果,降低成本;另外,副作用小,且治疗效果很好。
Description
技术领域
本发明属于动物疾病治疗与防御领域,尤其涉及一种用于动物退热的中药组合物。
背景技术
畜禽病毒性疾病是养殖业最难防治的一大类疾病,很多病毒可以通过空气传播,传播速度快,流行范围广,往往群发,且发病急,常伴随高热症状,发热对动物体有利也有害,发热时动物体免疫功能明显增强,这有利于清除病原体和促进疾病的痊愈,发热也是疾病的一个标志。体温不太高时不必急于用药,但是体温超过41℃,则可能引起惊厥、昏迷,甚至严重后遗症,故应及时退热。
而且由于病毒感染使动物体免疫下降,往往继发细菌、支原体和寄生虫感染,死亡率高。由于病毒变异极快,所以利用疫苗免疫预防效果往往不理想。目前常见的畜禽病毒性疾病如:猪圆环病毒病、蓝耳病、猪瘟、猪流感、猪伪狂犬病、鸡新城疫、鸡传染性法氏囊病、禽流感等。这些疫病在全世界范围内流行,每年因这些疾病造成畜禽死亡、生产性能降低、防治花费等给养殖业带来的经济损失数以亿计。
目前,治疗病毒性感染的人用化药和中药均很多,但由于受生物安全、药物残留及成本等因素限制,被批准兽用的抗病毒化药几乎没有,更没有纯中药的抗病毒化兽药,抗病毒中兽药制剂虽然不少,但临床效果确切且显著的却并不多。针对畜禽病毒感染引起的高热症状虽然有安乃近、对乙酰氨基酚、氨基比林、安替比林及氟尼辛葡甲胺等解热镇痛化学药物,但这些药物只能单纯解热,没有抗病毒作用,治标不治本,暂时控制症状后,经常出现反弹,虽然能一定程度降低死亡率,但存活下来的畜禽生产性能往往大受影响,从而大大降低了养殖的经济效益。目前临床上往往采用联合用药的方式防治各种畜禽病毒性感染引起的高热危重症,不但工作量大,应激大,成本高,且效果不理想。
发明内容
为了解决上述问题,本发明目的提供一种用于动物退热的中药组合物,利用该组合物制作的药物治疗效果非常理想,而且成本低。
柴胡清虚热中药,用于感冒发热、寒热往来、疟疾、肝郁气滞、胸肋胀痛、脱肛、子宫脱落、月经不调。
防风是中药材,是伞形科多年生草本植物防风的根;主治外感表证,风疹瘙痒,风湿痹痛,破伤风;功效为祛风解表,胜湿止痛,止痉定搐。
板蓝根与大青叶,皆有清热解毒凉血之功。但板蓝根有利咽之长,而大青叶化斑之长于胜于板蓝根。
紫花地丁味苦、辛、寒。归心、肺经。具有清热解毒,凉血消肿,清热利湿的作用,主治疔疮,痈肿,瘰疬,黄疸,痢疾,腹泻,目赤,喉痹,毒蛇咬伤。
小蓟凉血止血,祛瘀消肿。用于衄血,吐血,尿血,便血,崩漏下血,外伤出血,痈肿疮毒。
莲子心其味清苦,但却具有极好的降压去脂之效。
白茅根凉血,止血,清热,利尿。治热病烦渴,吐血,衄血,肺热喘急,胃热哕逆,淋病,小便不利,水肿,黄疸。
枳实,中药名为芸香科植物酸橙及其栽培变种或甜橙的干燥幼果。5~6月收集自落的果实,除去杂质,自中部横切为两半,晒干或低温干燥,较小者直接晒干或低温干燥。主治积滞内停;痞满胀痛;大便秘结;泻痢后重;结胸;胃下垂;子宫脱垂;脱肛。
为实现上述目的,本发明公开了一种用于动物退热的中药组合物,由以下重量份原料组分制备而成,柴胡190-210份、防风170-190份、板蓝根140-160份、紫花地丁90-110份、小蓟90-110份、莲子心90-110份、白茅根90-110份、枳实40-60份、山药10-30份。
本发明公开的上述一种用于动物退热的中药组合物,由以下重量份原料组分制备而成,柴胡200份、防风180份、板蓝根150份、紫花地丁100份、小蓟100份、莲子心100份、白茅根100份、枳实50份、山药20份。
本发明公开的上述一种用于动物退热的中药组合物,该组合物中还包括安乃近。
本发明公开的上述一种用于动物退热的中药组合物,由以下重量份原料组分制备而成,柴胡190-210份、防风170-190份、板蓝根140-160份、紫花地丁90-110份、小蓟90-110份、莲子心90-110份、白茅根90-110份、枳实40-60份、山药10-30份、安乃近190-205份。
本发明公开的上述一种用于动物退热的中药组合物,由以下重量份原料组分制备而成,柴胡200份、防风180份、板蓝根150份、紫花地丁100份、小蓟100份、莲子心100份、白茅根100份、枳实50份、山药20份、安乃近200份。
本发明的药物组合物可以制成其它剂型,但为更好的达到本发明的效果,本发明的药物组合物优选注射剂或口服制剂。其中,所述的口服制剂为口服液、颗粒剂或散剂。
本发明的药物组合物可按照常规的制剂制备方法处理各原料后制得,必要时可再加入适量的动物医学可接受的其他药用辅料。其中,所述的辅料包括附加剂、填充剂(稀释剂)、助流剂、粘合剂、矫味剂等。所述的附加剂包括:抑菌剂、增溶剂、助溶剂及pH调节剂及抗氧化剂等。附加剂可以是吐温80、苯甲醇、苯甲酸,丙二醇、乙醇、尼泊金类、盐酸、枸橼酸或氢氧化钠(钾)、碳酸氢钠、碳酸钠、磷酸盐、枸橼酸盐、亚硫酸钠、亚硫酸氢钠、焦亚硫酸钠、乙二胺四乙酸二钠等中的一种、两种或两种以上混合。所述的填充剂为乳糖、蔗糖粉、壳聚糖、滑石粉、淀粉、羧甲基淀粉钠、糊精、脱脂米糠、麦糠粉、麸皮、玉米芯粉、稻壳粉、小麦粗粉和大豆皮粉等中的一种、两种或两种以上混合。所述的助流剂为滑石粉、微粉硅胶的一种或两种混合。所述的粘合剂为羟丙甲纤维素、羧甲基纤维素钠、明胶、聚乙烯吡咯烷酮、糊精、聚乙二醇类辅料中的一种、两种或两种以上混合。所述的矫味剂为蔗糖、乳糖、葡萄糖、甜菊糖、甜菜碱、甜蜜素、三氯蔗糖、糖精钠、木糖醇、蛋白糖、果糖、柠檬油酪酸、乳酸丁酯、乳酸乙酯、茴香油、槟榔籽油和大葱油、香橙粉中的一种、两种或两种以上混合。
本发明的用于动物退热的中药组合物的注射剂和口服液的制备可按如下方法进行:1)将柴胡、防风、枳实分别粉碎,混合,加水浸泡后提取挥发油,与吐温-80以1:3比例混合备用,提取后的药液另器贮存;2)在1)中的提取挥发油后的药渣与板蓝根、紫花地丁、小蓟、莲子心、白茅根、山药,煎煮2~3次,与1)中药液一起合并煎液,浓缩,醇沉2次,回收乙醇,即得提取液,冷藏备用;3)取适量注射用水边加热边搅拌的情况下加入抗氧化剂溶解后,降温至40℃以下,加入1)中提取的挥发油和2)中所制备的提取液,搅拌均匀,加入适当的助溶剂使溶液澄明,还可以加入安乃近,在充氮状态下迅速搅拌至完全溶解,调pH值,过滤,分装,充氮,封口,灭菌,即得注射剂和口服液。
本发明的用于动物退热的中药组合物的颗粒剂的制备可按如下方法进行:1)将柴胡、防风、枳实,分别粉碎,混合,加水浸泡后提取挥发油,在挥发油中加入辅料环糊精,制备成环糊精包合物备用,提取后的药液另器贮存;2)在提取挥发油后的药渣与板蓝根、紫花地丁、小蓟、莲子心、白茅根、山药,加水煎煮两次,合并煎煮液,与1)中药液一起浓缩,醇沉,过滤回收乙醇,直接喷雾干燥成干浸膏粉,或浓缩成膏后再减压真空烘干,粉碎成浸膏粉;3)将1)中制得的挥发油包合物、2)中制得的浸膏粉及还可以有安乃近原粉充分混合,可拌入适量的矫味剂和润湿剂,置于混合机中搅拌制成软材,然后制粒,干燥,整粒,分装,即得。
本发明的用于动物退热的中药组合物的散剂的制备可按如下方法进行:
散剂制备方法(1):按照上述制备颗粒剂的制备方法制备挥发油环糊精包合物、浸膏粉,还可以将二者与安乃近原粉充分混合,然后加入矫味剂、填充剂至全量,充分混匀,过50目筛,分装,即得。
散剂制备方法(2):将柴胡、防风、板蓝根、紫花地丁、小蓟、莲子心、白茅根、枳实、山药,分别烘干,粉碎成50~300目的粉末,还可以加入安乃近后混合,可同时加入淀粉或微粉硅胶改善流动性,充分混匀,分装即得。
本发明具有如下优点:
(1)组方独特合理:畜禽外感发热时,往往伴有呼吸困难,咳嗽气喘、便秘、关节疼痛等症。上述几味药配合治疗畜禽外感发热,不但可以扶正祛邪、辛温解表、疏散退热,还可止痛温肺、润肠通便,且疗效显著,作用时间长;
(2)成本低:和组方一起使用的化药安乃近价格低廉,中药为常见药材。而且西复方制剂的用量比传统的中药用量少,施用方便,又能达到更好的效果,降低成本;
(3)毒副作用小:三倍剂量用药也未见毒副反应,而且在应用该组合物治疗畜禽疾病的过程中未发现明显不良反应。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。
实施例1
本实施例中药组合物由以下原料制得:柴胡200g、防风180g、板蓝根150g、紫花地丁100g、小蓟100g、莲子心100g、白茅根100g、枳实50g、山药20g。
制备过程如下:1)将柴胡、防风、枳实分别粉碎、混合,置挥发油提取器中,加水浸泡2小时,加水的量为药材总重量的4倍以上。煮沸回流6h以上充分提取挥发油,与吐温-80以1:3比例混合,备用,提取后的药液另器贮存;2)在1)中提取挥发油后的药渣与板蓝根、紫花地丁、小蓟、莲子心、白茅根、山药,加水煎煮3次,每次加入煎煮水的量为药材总重量的4倍以上,合并煎液,与1)中药液一起浓缩至原药材总量的0.5倍,加入乙醇,使醇的含量达60%,沉淀12h。回收乙醇后,再加入乙醇,使醇含量达70%,沉淀12h,回收乙醇,即得提取液,冷藏备用;3)取适量注射用水边加热边搅拌的情况下加入抗氧化剂亚硫酸氢钠36g溶解后,降温至40℃以下,加入1)中提取的挥发油和2)中所制备的提取液,搅拌均匀,加入适量的吐温80使溶液澄明,在充氮状态下迅速搅拌至完全溶解,调pH值至4.5,加注射用水至总量10000ml,过滤,分装,充氮,封口,灭菌,即得注射液。
实施例2
本实施例中药组合物由以下原料制得:柴胡200g、防风180g、板蓝根150g、紫花地丁100g、小蓟100g、莲子心100g、白茅根100g、枳实50g、山药20g、安乃近200g。
制备过程如下:1)将柴胡、防风、枳实分别粉碎、混合,置挥发油提取器中,加水浸泡2小时,加水的量为药材总重量的4倍以上。煮沸回流6h以上充分提取挥发油,与吐温-80以1:3比例混合,备用;2)在1)中提取挥发油后的药渣与板蓝根、紫花地丁、小蓟、莲子心、白茅根、山药,加水煎煮3次,每次加入煎煮水的量为药材总重量的4倍以上,合并煎液,与1)中药液一起浓缩至原药材总量的0.5倍,加入乙醇,使醇的含量达60%,沉淀12h。回收乙醇后,再加入乙醇,使醇含量达70%,沉淀12h,回收乙醇,即得提取液,冷藏备用;3)取适量注射用水边加热边搅拌的情况下加入抗氧化剂亚硫酸氢钠36g溶解后,降温至40℃以下,加入1)中提取的挥发油和2)中所制备的提取液,搅拌均匀,加入适量的吐温80使溶液澄明,再加入安乃近,在充氮状态下迅速搅拌至完全溶解,调pH值至4.5,加注射用水至总量10000ml,过滤,分装,充氮,封口,灭菌,即得注射液。
实施例3
本实施例中药组合物由以下原料制得:柴胡200g、防风180g、板蓝根150g、紫花地丁100g、小蓟100g、莲子心100g、白茅根100g、枳实50g、山药20g。
按照实施例1制备注射液的方法制备口服液即得。
实施例4
本实施例中药组合物由以下原料制得:柴胡200g、防风180g、板蓝根150g、紫花地丁100g、小蓟100g、莲子心100g、白茅根100g、枳实50g、山药20g、安乃近200g。
按照实施例2制备注射液的方法制备口服液即得。
实施例5
本实施例中药组合物由以下原料制得:柴胡200g、防风180g、板蓝根150g、紫花地丁100g、小蓟100g、莲子心100g、白茅根100g、枳实50g、山药20g。
制备过程如下:1)将柴胡、防风、枳实分别粉碎,混合,置入挥发油提取器中,加水浸泡2小时,加水的量以没过药材为宜为药材总重量的4倍以上。煮沸回流6h以上充分提取挥发油,在挥发油中加入辅料β-环糊精,制备成环糊精包合物,备用;2)在提取挥发油后的药渣与板蓝根、紫花地丁、小蓟、莲子心、白茅根、山药,煎煮三次,每次加水量以没过药材为宜,合并煎煮液,与1)中药液一起浓缩至药材总量的0.5倍,加入乙醇,使醇含量达60%,沉淀12小时,过滤回收乙醇,直接喷雾干燥成干浸膏粉;3)将1)中制得的挥发油包合物、2)中制得的浸膏粉充分混合,可拌入适量的乳糖作为填充剂和矫味剂,使总量达13400g,加入适量60%作乙醇作为矫味剂和乙醇作为润湿剂,置于混合机中搅拌制成软材,然后制粒,干燥,整粒,分装,即得颗粒剂。
实施例6
本实施例中药组合物由以下原料制得:柴胡200g、防风180g、板蓝根150g、紫花地丁100g、小蓟100g、莲子心100g、白茅根100g、枳实50g、山药20g、安乃近200g。
制备过程如下:1)将柴胡、防风、枳实分别粉碎,混合,置入挥发油提取器中,加水浸泡2小时,加水的量以没过药材为宜为药材总重量的4倍以上。煮沸回流6h以上充分提取挥发油,在挥发油中加入辅料β-环糊精,制备成环糊精包合物,备用;2)在提取挥发油后的药渣与板蓝根、紫花地丁、小蓟、莲子心、白茅根、山药,煎煮三次,每次加水量以没过药材为宜,合并煎煮液与1)中药液一起,浓缩至药材总量的0.5倍,加入乙醇,使醇含量达60%,沉淀12小时,过滤回收乙醇,直接喷雾干燥成干浸膏粉;3)将1)中制得的挥发油包合物、2)中制得的浸膏粉及安乃近原粉充分混合,可拌入适量的乳糖作为填充剂和矫味剂,使总量达13400g,加入适量60%作乙醇作为矫味剂和乙醇作为润湿剂,置于混合机中搅拌制成软材,然后制粒,干燥,整粒,分装,即得颗粒剂。
实施例7
本实施例中药组合物由以下原料制得:柴胡200g、防风180g、板蓝根150g、紫花地丁100g、小蓟100g、莲子心100g、白茅根100g、枳实50g、山药20g。
将上述九味中药烘干粉碎成50目的粉末,充分混匀,分装,即得散剂。
实施例8
本实施例中药组合物由以下原料制得:柴胡200g、防风180g、板蓝根150g、紫花地丁100g、小蓟100g、莲子心100g、白茅根100g、枳实50g、山药20g、安乃近200g。
将上述九味中药烘干粉碎成50目的粉末,混合后再混入安乃近,充分混匀,分装,即得散剂。
实施例9
本发明中药组合物对松节油致热家兔体温的影响效果
1试验材料与方法
1.1试验药物:试验药物为本发明实施例1制备注射液和本发明实施例2制备注射液;对照药物为市售的含量为30%的安乃近注射液,实施例2制备制剂的安乃近药物含量为1ml∶1.4g(中药材)。
1.2试验动物健康家兔40只,平均体重为2.2±0.3公斤。
1.3试验方法将家兔随机平均分为4组,每组10只。给所有试验兔背部皮下注射松节油0.4ml/kg,24小时后家兔体温平均升高2.0℃左右。给第1、2、3组分别肌内注射本发明实施例2制备注射液、对照药物和本发明实施例1制备注射液0.5ml/kg;第4组为空白对照组,肌肉注射生理盐水0.5ml/kg。给药后第0.5h、1h、2h、3h、4h、5h、6h、12h各测一次体温。
2试验结果与分析
试验结果,见表1
表1本发明药物对松节油致热家兔体温的影响效果
结果发现:安乃近注射液组的体温在用药1小时内迅速下降至近正常体温,但维持不到3小时后又开始反弹;中药注射液对照组在用药1小时后体温有所下降,一直维持到12小时,但未降低至正常体温范围;本发明药物在用药1小时内迅速下降至近正常体温,到12小时后体温仍然低于用药前水平,退热作用可以维持10小时以上。试验结果证明,本发明药物退热消炎作用强而持久,能使人工致热的家兔体温降至正常水平,其退热消炎作用显著优于安乃近注射液和纯中药注射液。
实施例10
本发明中药组合物应用于猪、鸡的毒副作用观察
1试验材料与方法
1.1试验药物:试验药物为实施例2制备注射液和实施例6制备的颗粒剂。
1.2试验动物健康仔猪60头,平均体重为30±0.55公斤。健康10日龄雏鸡120只。
1.3试验方法将仔猪随机分为4组,每组15头。第1、2、3组为试验组,分别肌肉注射实施例1制备的注射液0.3ml/kg、0.6ml/kg、0.9ml/kg,每天1次,连用3天;第4组为空白对照组,不给药,正常饲养。对所有试验仔猪用药后观察15天,记录不良反应、饮食欲、精神状态及体重变化等情况。
将雏鸡随机分为4组,每组30只,第1、2、3组为试验组,将实施例3制备的颗粒剂分别按照2g∶1kg、4g∶1kg、6g∶1kg的比例兑水,搅拌溶解,分别给前3组雏鸡自由饮用,每天饮药水2小时,连饮3天;第4组为空白对照组,不给药,正常饲养。对所有试验雏用药后观察15天,记录不良反应、饮食欲、精神状态及体重变化等情况。
2试验结果与分析
与未用药的对照组比较,前3组用药的仔猪均未发生明显不良反应,饮食欲、精神状态均正常,平均体重增长差异也不大。
与未用药的对照组比较,前3组用药的雏鸡均未发生明显不良反应,饮食欲、精神状态均正常,平均体重增长差异不大。
上述试验结果说明,本发明药物毒副作用小,应用后不会影响动物的生长发育。
实施例11
本发明中药组合物治疗猪蓝耳病的效果
1.材料与方法
1.1试验药物试验药物为本发明实施例1制备注射液和本发明实施例2制备注射液;对照药物为市售的含量为30%的安乃近注射液,实施例2制备制剂的安乃近药物含量为1ml∶1.4g(中药材)。
1.2试验动物自然感染猪蓝耳病的80头育肥猪。
2014年12月,寒流侵袭,北京某养殖场的100多头育肥猪突然发病,体温升高达40℃以上,眼结膜发炎,眼睑水肿,咳嗽,气喘等呼吸道症状;部分猪皮肤表现青紫色,后躯无力、不能站立或共济失调等神经症状。根据发病情况、临床症状和病理变化,初步诊断该猪群为蓝耳病毒感染。挑选其中体重相近,病情典型的猪80头进行试验,观察本发明药物的临床疗效。
1.3试验方法将80头病猪随机分为4组,每组20头。第1组为本发明实施例2制备药物组,肌内注射本发明药物0.3ml/kg,1天1次,连用3天;第2组为安乃近注射液对照组,肌内注射对照药物,用法用量同第1组;第3组为本发明实施例1制备药物组,肌内注射中药组合物,用法用量同第1组;第4组为空白对照组,不给药。对所有试验动物,用药期间及用药后连续观察15天,每天记录死亡数、症状变化、饮、欲及精神状态等情况。
1.4疗效判定标准无效:给药及观察期内,没有效果或效果不明显视为无效;有效:给药及观察期内各种临床症状缓解,体温降低,眼睑水肿、皮肤颜色、呼吸困难及神经症状等好转,精神状态好转,食欲增加,或完全治愈的猪均视为有效;治愈:各种临床症状消失,体温、呼吸恢复正常,食欲、精神状态良好,停药一周后不复发。
2.试验结果与分析
试验结果见表2。试验数据采用SPSS12.0软件进行方差分析,对试验结果数据进行显著性检验。
表2猪蓝耳病的治疗效果
试验结果发现:在试验过程中,本发明药物组的猪除了试验初期一头猪因发病太急死亡外,其他猪全部存活并好转,本发明实施例2制备药物治疗组的总有效率为95%,治愈率为75%;安乃近注射液对照组的总有效率为60%,治愈率仅为45%;本发明实施例1制备的纯中药注射液总有效率80%,治愈率为60%;不给药的对照组总有效率为55%,痊愈率也仅为40%。从试验结果可以看出,前3组用药组的效果要好于第4组不用药对照组,但经x2检验,安乃近注射液对照组与空白对照组的差异不显著(P≥0.05),即无统计学明显差异,这是因为安乃近只有单纯解热消炎镇痛作用,没有抗病毒作用,所以对蓝耳病这类病毒性疾病治疗效果不佳;本发明实施例1制备的纯中药注射液组与空白对照组相比,差异显著(0.01<P<0.05),说明本发明中药组份有很明显的抗病毒效果;本发明实施例2制备的药物组与安乃近注射液对照组相比,差异极显著(P<0.01),与本发明实施例1制备的纯中药注射液组相比差异显著(0.01<P<0.05),说明本发明的中西复方药物组合物能标本兼治,对猪蓝耳病这类外感发热病有极佳的疗效。
实施例12
本发明中药组合物治疗猪蓝耳病的效果
1.材料与方法
1.1试验药物取实施例8制备的散剂作为试验药物。
1.2试验动物上述发生蓝耳病的猪场中未发病的育肥猪100头
1.3试验方法将试验动物分为2组,每组50头,第1组为药物试验组,每吨饲料拌入试验药物2公斤,饲喂1周;另外1组为空白对照组,不给药,正常饲养。对所有试验动物,在用药期间及用药后连续观察21天,记录发病情况、饮食欲、精神状态等情况。
2.试验结果与分析
试验结果见表3
表3预防猪蓝耳病的效果
试验过程中,本发明药物组的猪在试验第1、2天分别有3头和1头猪出现高热、咳嗽的症状,在几天继续给药后4头猪病情好转,除了这4头外未见其他猪出现明显临床症状;空白对照组的猪在观察期内每天都有头数不等的猪发病,截止第20天一共有26头猪出现明显临床症状。试验结果说明本发明药物组的保护率达92%,对猪蓝耳病的预防有极好的效果。
实施例13
本发明中药组合物治疗鸡新城疫与巴氏杆菌混合感染的效果
1材料与方法
1.1试验药物:试验药物为本发明实施例3制备颗粒剂和本发明实施例6制备颗粒剂作为试验药物;实施例6制备制剂的安乃近药物含量为1∶2(中药材),对照药物为自制的安乃近颗粒剂,其制备方法:取和实施例6相同处方量的安乃近原粉,加入相同的辅料制备成颗粒剂,其安乃近含量和实施例6制备的颗粒剂中安乃近含量相同均为30%。
1.2试验动物440只鸡新城疫与巴氏杆菌混合感染的病鸡。
2014年1月,北京某养鸡场3000多只成鸡群发生传染病,刚开始部分鸡出现体温升高43~43.5℃,摇头,张口呼吸,不吃食,喜饮水。几天后病情蔓延至整个鸡群,并有鸡开始死亡。大部分鸡精神沉郁,食欲下降,羽毛粗乱无光,嗜睡,排黄绿色稀粪,嗉囊膨胀,口腔流出大量的黏液,张口呼吸,少数病鸡出现神经症状。病理解剖见盲肠扁桃体肿大、出血;小肠、盲肠粘膜有出血点;腺胃乳头有出血点、坏死。根据发病情况、剖检的病理变化及实验室病原菌检查初步诊断为鸡新城疫和巴氏杆菌混合感染。为了验证本发明药物的疗效,我们挑选了症状典型的440只病鸡作为试验动物。
1.3试验方法将440只病鸡随机分为4组,每组110只。第1组为本发明实施例6制备的药物组,将实施例6制备的颗粒剂100g兑水50公斤,让鸡自由饮用,连饮5天,同时在饲料中拌入复方磺胺嘧啶预混剂进行抗菌治疗,让鸡自由采食,连用5天;第2组为本发明实施例5制备的纯中药颗粒剂组,饮水中加入实施例6制备的颗粒剂,用法用量同第1组,同时也应用复方磺胺嘧啶预混剂进行抗菌治疗;第3组为安乃近颗粒剂对照组,饮水中加入安乃近颗粒剂,用法用量同第1组,同时也应用复方磺胺嘧啶预混剂进行抗菌治疗;第4组为空白对照组,只用复方磺胺嘧啶预混剂进行抗菌治疗。对所有试验动物,用药期间及用药后连续观察20天,每天记录死亡数、症状变化、饮食欲及精神状态等情况。
1.4疗效判定标准无效:给药及观察期内,没有效果或效果不明显视为无效;有效:给药及观察期内各种临床症状缓解,呼吸道症状明显好转,腹泻减轻,食欲、精神状态好转,或完全治愈的鸡均视为有效;治愈:各种临床症状消失,呼吸恢复正常、排便正常,食欲、精神状态良好,停药一周后不复发。
2试验结果与分析
试验结果见表4。试验数据采用SPSS12.0软件进行方差分析,试验结果数据进行显著性检验。
表4治疗鸡新城疫与禽霍乱混合感染的效果
本发明实施例3中药组合物组的总有效率为96%,痊愈率为84%安乃近颗粒剂对照组的总有效率为76.7%,治愈率为65.3%;空白对照组的总有效率为60.7%,治愈率为50%。从试验结果可以看出,应用退热药的前2组要好于第3组,说明针对鸡发病后体温升高的症状,及时应用退热药有非常好的协同治疗效果。经x2检验,本发明实施例3中药组合物与安乃近颗粒剂相比差异极显著(P<0.01),说明本发明中药组合物的效果更佳,对鸡新城疫与禽霍乱混合感染有这极佳的治疗效果。
虽然,上文中已经用一般性说明及具体实施例对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (7)
1.一种用于动物退热的中药组合物,其特征在于:所述中药组合物由以下重量份原料组分制备而成,柴胡190-210份、防风170-190份、板蓝根140-160份、紫花地丁90-110份、小蓟90-110份、莲子心90-110份、白茅根90-110份、枳实40-60份、山药10-30份。
2.如权利要求1所述的一种用于动物退热的中药组合物,其特征在于:所述中药组合物由以下重量份原料组分制备而成,柴胡200份、防风180份、板蓝根150份、紫花地丁100份、小蓟100份、莲子心100份、白茅根100份、枳实50份、山药20份。
3.如权利要求1所述的一种用于动物退热的中药组合物,其特征在于:所述中药组合物还包括安乃近。
4.如权利要求3所述的一种用于动物退热的中药组合物,其特征在于:所述中药组合物由以下重量份原料组分制备而成,柴胡190-210份、防风170-190份、板蓝根140-160份、紫花地丁90-110份、小蓟90-110份、莲子心90-110份、白茅根90-110份、枳实40-60份、山药10-30份、安乃近190-205份。
5.如权利要求4所述的一种用于动物退热的中药组合物,其特征在于:所述中药组合物由以下重量份原料组分制备而成,柴胡200份、防风180份、板蓝根150份、紫花地丁100份、小蓟100份、莲子心100份、白茅根100份、枳实50份、山药20份、安乃近200份。
6.根据权利要求1-5任一项所述的一种用于动物退热的中药组合物,其特征在于:所述中药组合物为注射剂或口服制剂。
7.根据权利要求6所述的一种用于动物退热的中药组合物,其特征在于:所述口服制剂为口服液、颗粒剂或散剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611218182.5A CN106511819A (zh) | 2016-12-26 | 2016-12-26 | 一种用于动物退热的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611218182.5A CN106511819A (zh) | 2016-12-26 | 2016-12-26 | 一种用于动物退热的中药组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106511819A true CN106511819A (zh) | 2017-03-22 |
Family
ID=58337934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611218182.5A Pending CN106511819A (zh) | 2016-12-26 | 2016-12-26 | 一种用于动物退热的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106511819A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107625902A (zh) * | 2017-09-26 | 2018-01-26 | 覃益祥 | 一种调节肝功能的中药组合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102379939A (zh) * | 2010-09-06 | 2012-03-21 | 北京大北农动物保健科技有限责任公司 | 一种防治畜禽外感发热的药物组合物 |
-
2016
- 2016-12-26 CN CN201611218182.5A patent/CN106511819A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102379939A (zh) * | 2010-09-06 | 2012-03-21 | 北京大北农动物保健科技有限责任公司 | 一种防治畜禽外感发热的药物组合物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107625902A (zh) * | 2017-09-26 | 2018-01-26 | 覃益祥 | 一种调节肝功能的中药组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104068279B (zh) | 一种含有中药添加剂的鳗鱼饲料及其制备方法 | |
CN105166544A (zh) | 一种猪配合饲料及其制备方法 | |
CN104799003A (zh) | 一种10-30日龄仔猪的配合饲料及其制备方法 | |
CN102379920B (zh) | 一种兽用抗病毒退热药物组合物 | |
CN103960542B (zh) | 一种用于防治猪附红细胞体病的饲料和中药组合物 | |
CN102379939B (zh) | 一种防治畜禽外感发热的药物组合物 | |
CN103251741A (zh) | 一种治疗猪弓形虫病的中药组合物及其制备方法和应用 | |
CN106511819A (zh) | 一种用于动物退热的中药组合物 | |
CN106359994A (zh) | 仔猪饲料 | |
CN105535094A (zh) | 一种促进畜禽和鱼类生产性能的中药组合物 | |
CN106728266A (zh) | 一种用于防治禽曲霉菌病的中药制剂 | |
CN104083729A (zh) | 一种防治毛皮动物混合感染的药物及其制备方法和应用 | |
CN107412738A (zh) | 一种治疗宠物病毒性风寒感冒的营养膏及其制备方法 | |
CN103393891B (zh) | 一种抗病毒兽用复方中药及其制备方法和用途 | |
CN105166543A (zh) | 一种牛配合饲料及其制备方法 | |
CN101972325A (zh) | 用于治疗鸡球虫病的药物组合物及其制备方法 | |
CN101711795B (zh) | 一种兽用解热抗病毒药物组合物 | |
CN105998783A (zh) | 一种治疗鸡免疫力低下的中药口服液 | |
CN111588801A (zh) | 一种预防畜禽疫病的中药分散颗粒剂及其制备方法 | |
CN115671192B (zh) | 一种防治鸭绦虫病的中药组合物 | |
CN102380085B (zh) | 一种兽用退热抗呼吸道感染的药物组合物 | |
CN102397510B (zh) | 一种治疗鸡马立克氏病的复方蜂胶组合物及其制备方法 | |
CN107596337B (zh) | 一种增加短肠综合症患者肠道吸收面积的药物组合物 | |
CN102397530B (zh) | 一种治疗禽传染性脑脊髓炎的复方蜂胶组合物及其制备方法 | |
CN102379945B (zh) | 一种兽用中西复方退热消炎药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170322 |
|
RJ01 | Rejection of invention patent application after publication |